Subject:
- Active Substance: Brolucizumab
- Name: Beovu®
- Therapeutic area: Visual impairment due to diabetic macular edema
- Pharmaceutical company: Novartis Pharma GmbH
Time table:
- Start: 01.05.2022
- Final decision by G-BA: 20.10.2022
Final decision:
- No additional benefit proved